TELA Bio Inc
telabio.comWhat Do They Do?
Sells reinforced tissue matrices for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery to hospitals and ambulatory surgery centers.
10-K for FY2025, filed Mar 25, 2026Our first portfolio of products, the OviTex Reinforced Tissue Matrix (“OviTex”) which we first commercialized in the U.S. in July 2016 and…View ↗
Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and…View ↗
Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, (“OviTex PRS”) which we first commercialized in the U.S. in May…View ↗
The majority of our products are shipped directly from Auckland, New Zealand to our headquarters in Malvern, Pennsylvania. We sell our…View ↗
How Do They Make Money?
Hospitals and surgical facilities buy the products. Non-consigned sales are counted at shipment or delivery; consigned sales are counted when the product is used in surgery, and customer payment terms are no more than one year.
10-K for FY2025, filed Mar 25, 2026A significant portion of the Company’s revenue is generated from product shipped to a customer or from consigned inventory maintained at…View ↗
F-12 when control is transferred to the customer, which occurs at the time the product is used in a surgical procedure. For product that is…View ↗
Payment terms with customers do not exceed one year and, therefore, the Company does not account for a financing component in these…View ↗
The majority of our products are shipped directly from Auckland, New Zealand to our headquarters in Malvern, Pennsylvania. We sell our…View ↗
$80.3M
-
10-K for FY2025, filed Mar 25, 2026
$80.3M ↗
Who Are Their Customers?
Hospitals and ambulatory surgery centers are direct customers; the company also uses independent contractors and distributors in the United States and some European countries.
10-K for FY2025, filed Mar 25, 2026
Do Revenues Turn Into Profits?
No. It lost $38.8M in FY2025.
10-K for FY2025, filed Mar 25, 2026
−$33.8MView ↗
10-K for FY2025, filed Mar 25, 2026
−$38.8MView ↗
10-K for FY2025, filed Mar 25, 2026
−$28.7MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$11.3MView ↗
- ▲ +13% (Loss)
- vs −$9.9M in Q2 FY2025
-
Aug 31, 2026
CFO and COO Roberto Cuca stepped down
The company plans an approximately 20% workforce reduction and says the initiative targets $17.0 million in annual expense savings.
Sources
8-K, filed Aug 31, 2026
Ms. Getz continued, “At the same time, we are implementing a broader initiative to strengthen our cost structure and position TELA Bio for…View ↗
-
Aug 10, 2026
TELA Bio withdrew its full-year 2026 revenue guidance
The company said it would provide an update in the future.
Sources
8-K, filed Aug 10, 2026
Ms. Getz continued, “Given the confluence of these dynamics, we are withdrawing our full year 2026 revenue guidance as I fully assess the…View ↗
-
Aug 4, 2026
Antony Koblish departed as CEO and Heather Getz was appointed
Sources
8-K, filed Aug 4, 2026
On August 3, 2026, the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”) determined that, Antony Koblish will no longer…View ↗
Growing. Revenue grew 2.7x in 4 years, from $29.5M in FY2021 to $80.3M in FY2025, about 28% a year.
Dedicated inguinal-repair product
TELA Bio added OviTex IHR, a configuration designed specifically for inguinal hernia procedures performed robotically or laparoscopically, beyond the earlier OviTex configurations for hernia repair.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and…View ↗
Our OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and…View ↗
Expanded OviTex PRS line
The OviTex PRS line expanded with a long-term resorbable configuration and larger sizes, building on the PRS products described earlier.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (“OviTex PRS”), which we first commercialized in the U.S. in May…View ↗
Our second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, (“OviTex PRS”) which we first commercialized in the U.S. in May…View ↗
Changed partner-distributed products
TELA Bio added LIQUIFIX to its partner-distributed offerings, while NIVIS shifted from its portfolio to distribution rights sold to MiMedx.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 25, 2026We also continue to expand our service offerings and diversify our supplier base as we continue to create a soft tissue restoration…View ↗
Historically, we have sought to expand our service offerings beyond our OviTex and OviTex PRS products through commercial partnerships to…View ↗
Who Do They Compete With?
Competes with Bard, Allergan, MTF Biologics, Novadaq, RTI Surgical, and Integra Lifesciences
10-K for FY2025, filed Mar 25, 2026In the hernia repair market, our primary competitors are Bard, a subsidiary of Becton, Dickinson and Company, which produces Phasix and…View ↗
Loading...
